Fecal Calprotectin Monitoring in Inflammatory Bowel Disease

Monitoring Frequency

For outpatient monitoring of inflammatory bowel disease, fecal calprotectin should be tested every 3-6 months in patients with symptomatic remission and every 2-4 months in patients with active disease or recent treatment adjustments, as recommended by the guideline society 1
The American Gastroenterological Association recommends testing fecal calprotectin every 3-6 months in patients with recent symptomatic remission (within 1-3 months of treatment adjustment) 2
For patients with stable disease and consistent symptomatic remission, the guideline society recommends testing fecal calprotectin every 6-12 months 1

Fecal calprotectin <150 μg/g suggests minimal inflammation and can reliably rule out active inflammation in patients in symptomatic remission, with a strength of evidence based on studies published in Gastroenterology 3, 2
A lower cutoff of <50 μg/g may be preferred to detect endoscopic improvement in patients who have recently achieved symptomatic remission after treatment adjustment, as suggested by the American Gastroenterological Association 2
Fecal calprotectin >150 μg/g suggests possible active inflammation and may warrant further evaluation, according to the guideline society 2

Fecal calprotectin may identify patients with early recurrence and should be checked at 3 months post-surgery and after first endoscopy, as recommended by the European Crohn’s and Colitis Organisation 4, 5
Symptoms alone are inadequate when monitoring for post-operative recurrence, making biomarker monitoring essential, with a strength of evidence based on studies published in the Journal of Crohn's and Colitis 4, 5
For patients with predominantly small bowel Crohn's disease, consider complementing fecal calprotectin with other monitoring methods, as suggested by the guideline society 1

If there is discordance between biomarkers (e.g., normal calprotectin but elevated lactoferrin), repeat measurement in 3-6 months before proceeding to endoscopy, as recommended by the American Gastroenterological Association 6
For patients with elevated biomarkers but no symptoms, repeat testing in 3-6 months is reasonable before proceeding to endoscopy, according to the guideline society 1

Calprotectin levels <50 μg/g reliably indicate absence of active inflammation in patients with IBD who are in symptomatic remission, with a sensitivity of 90.6% for detecting endoscopically active disease, according to the American Gastroenterological Association 7
In asymptomatic UC patients on stable maintenance therapy, approximately 15% still have moderate to severe endoscopic inflammation despite being symptom-free, as reported by the American Gastroenterological Association 8

Normal calprotectin (<150 μg/g) has a false-negative rate of 26.4% in Crohn's disease patients with moderate to severe symptoms, meaning over one-quarter of symptomatic patients with normal calprotectin actually have endoscopic activity, as stated by the American Gastroenterological Association 9
The American Gastroenterological Association recommends endoscopic assessment of disease activity rather than empiric treatment adjustment for patients with mild symptoms and normal biomarkers (calprotectin <150 μg/g, CRP <5 mg/L) 9

For ruling out inflammation, the American Gastroenterological Association suggests using calprotectin <50 μg/g in asymptomatic patients or those recently achieving remission, with a sensitivity of 92% but specificity of only 60% 7, 8
For confirming inflammation, the American Gastroenterological Association recommends using calprotectin >250 μg/g, which provides specificity of 82% but sensitivity drops to 80% 7

Variability exists between different assays, between stool samples from the same patient during one day, and related to interval between stools, as noted by the European Society of Gastrointestinal Endoscopy 7, 10
The European Society of Gastrointestinal Endoscopy recommends using the first stool passed in the morning and storing for no more than 3 days at room temperature before analysis 7, 10